{"id":33909,"date":"2020-09-10T15:50:30","date_gmt":"2020-09-10T13:50:30","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=33909"},"modified":"2022-05-12T15:16:51","modified_gmt":"2022-05-12T13:16:51","slug":"09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs","status":"publish","type":"post","link":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/","title":{"rendered":"10. September 2020 | Dermapharm Holding SE schlie\u00dft Kooperations- und Liefervereinbarung mit BioNTech SE"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8220;1&#8243; admin_label=&#8220;section&#8220; _builder_version=&#8220;4.16&#8243; da_disable_devices=&#8220;off|off|off&#8220; global_colors_info=&#8220;{}&#8220; da_is_popup=&#8220;off&#8220; da_exit_intent=&#8220;off&#8220; da_has_close=&#8220;on&#8220; da_alt_close=&#8220;off&#8220; da_dark_close=&#8220;off&#8220; da_not_modal=&#8220;on&#8220; da_is_singular=&#8220;off&#8220; da_with_loader=&#8220;off&#8220; da_has_shadow=&#8220;on&#8220;][et_pb_row column_structure=&#8220;1_2,1_2&#8243; column_padding_mobile=&#8220;on&#8220; admin_label=&#8220;Zeile&#8220; _builder_version=&#8220;4.17.3&#8243; background_size=&#8220;initial&#8220; background_position=&#8220;top_left&#8220; background_repeat=&#8220;repeat&#8220; width=&#8220;100%&#8220; custom_padding=&#8220;|0px||0px|false|true&#8220; hover_enabled=&#8220;0&#8243; make_fullwidth=&#8220;off&#8220; use_custom_width=&#8220;off&#8220; width_unit=&#8220;on&#8220; global_colors_info=&#8220;{}&#8220; sticky_enabled=&#8220;0&#8243;][et_pb_column type=&#8220;1_2&#8243; _builder_version=&#8220;4.16&#8243; custom_padding=&#8220;|||&#8220; global_colors_info=&#8220;{}&#8220; custom_padding__hover=&#8220;|||&#8220;][et_pb_text admin_label=&#8220;Schaltfl\u00e4che %22zur\u00fcck zum Archiv%22&#8243; _builder_version=&#8220;4.16&#8243; background_size=&#8220;initial&#8220; background_position=&#8220;top_left&#8220; background_repeat=&#8220;repeat&#8220; text_orientation=&#8220;left&#8220; use_border_color=&#8220;off&#8220; border_color=&#8220;#ffffff&#8220; border_style=&#8220;solid&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<style> .zur\u00fcckbutton:before {display: inline-block; font-family: \"ETmodules\"; content: \"\\4a\"; color: #00225f; margin-right: 7px;} .zur\u00fcckbutton:hover:before {display: inline-block; font-family: \"ETmodules\"; content: \"\\4a\"; color: #d85710; margin-right: 7px;}<\/style>\n<h1>Ad-Hoc-Mitteilung<\/h1>\n<p><a class=\"zur\u00fcckbutton\" href=\"https:\/\/dev.cometis.de\/veroeffentlichungsarchiv-dermapharm\">zum Archiv<\/a><br \/>\n[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8220;1_2&#8243; _builder_version=&#8220;4.16&#8243; custom_padding=&#8220;|||&#8220; global_colors_info=&#8220;{}&#8220; custom_padding__hover=&#8220;|||&#8220;][et_pb_image src=&#8220;https:\/\/dev.cometis.de\/wp-content\/uploads\/2018\/08\/autodoc_Logo_Wei%C3%9F_2-7.png&#8220; align=&#8220;right&#8220; align_tablet=&#8220;center&#8220; align_phone=&#8220;center&#8220; align_last_edited=&#8220;on|desktop&#8220; admin_label=&#8220;Logo&#8220; _builder_version=&#8220;4.16&#8243; use_border_color=&#8220;off&#8220; border_color=&#8220;#ffffff&#8220; border_style=&#8220;solid&#8220; animation=&#8220;off&#8220; sticky=&#8220;off&#8220; always_center_on_mobile=&#8220;on&#8220; global_colors_info=&#8220;{}&#8220;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=&#8220;row&#8220; _builder_version=&#8220;4.17.3&#8243; background_size=&#8220;initial&#8220; background_position=&#8220;top_left&#8220; background_repeat=&#8220;repeat&#8220; width=&#8220;100%&#8220; custom_padding=&#8220;0px|0px|0px|0px|true|true&#8220; hover_enabled=&#8220;0&#8243; global_colors_info=&#8220;{}&#8220; sticky_enabled=&#8220;0&#8243;][et_pb_column type=&#8220;4_4&#8243; _builder_version=&#8220;4.16&#8243; custom_padding=&#8220;|||&#8220; global_colors_info=&#8220;{}&#8220; custom_padding__hover=&#8220;|||&#8220;][et_pb_text admin_label=&#8220;Text&#8220; _builder_version=&#8220;4.16&#8243; background_size=&#8220;initial&#8220; background_position=&#8220;top_left&#8220; background_repeat=&#8220;repeat&#8220; text_orientation=&#8220;left&#8220; use_border_color=&#8220;off&#8220; border_color=&#8220;#ffffff&#8220; border_style=&#8220;solid&#8220; saved_tabs=&#8220;all&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<h1><strong><em>Dermapharm Holding SE schlie\u00dft Kooperations- und Liefervereinbarung mit BioNTech SE<\/em><\/strong><\/h1>\n<p>Gr\u00fcnwald, 10. September 2020 &#8211; Die Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) und die BioNTech SE, Mainz, Deutschland sind \u00fcbereingekommen, dass ihre Produktionstochtergesellschaften bei der Herstellung des COVID-19 Impfstoffes kooperieren werden. Die Produktionskapazit\u00e4ten bei Dermapharm stehen bereits zu Beginn der Impfstoffproduktion den Kooperationspartnern BioNTech SE und Pfizer Inc. zur Verf\u00fcgung.<\/p>\n<p><strong>Kontakt<\/strong><br \/>\nInvestor Relations<br \/>\n&amp; Corporate Communications<br \/>\nBritta Hamberger<br \/>\nTel.: +49 (0)89 \u2013 64186-233<br \/>\nFax: +49 (0)89 \u2013 64186-165<br \/>\nE-Mail: <a href=\"mailto:ir@dermapharm.com\">ir@dermapharm.com<\/a><\/p>\n<p>cometis AG<br \/>\nClaudius Krause<br \/>\nTel.: +49 (0)611 \u2013 205855-28<br \/>\nFax: +49 (0)611 \u2013 205855-66<br \/>\nE-Mail: <a href=\"mailto:ir@dermapharm.com\">ir@dermapharm.com<\/a><br \/>\n[\/et_pb_text][et_pb_text admin_label=&#8220;Schaltfl\u00e4che %22Beitrag als PDF%22&#8243; _builder_version=&#8220;4.16&#8243; background_size=&#8220;initial&#8220; background_position=&#8220;top_left&#8220; background_repeat=&#8220;repeat&#8220; text_orientation=&#8220;left&#8220; use_border_color=&#8220;off&#8220; border_color=&#8220;#ffffff&#8220; border_style=&#8220;solid&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<div class=\"leseprobe-archiv\"><a title=\"Beitrag als PDF\" href=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2020\/09\/DE_20200910_Ad-hoc_Biontech-FINAL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Beitrag als PDF<\/a><\/div>\n<style> .leseprobe-archiv {color: #00225f !important; border-color: #00225f; position: relative; padding: 0.3em 1em; border: 1px solid; -webkit-border-radius: 3px; -moz-border-radius: 3px; border-radius: 3px; -webkit-transition: all 0.2s; -moz-transition: all 0.2s; transition: all 0.2s; padding:10px; width: 19%; text-align: center; margin-right: 10px; float:left;} .leseprobe-archiv:hover {background-color: #eee; border-color: #ffffff; cursor: pointer;}<\/style>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ad-Hoc-Mitteilung zum Archiv Dermapharm Holding SE schlie\u00dft Kooperations- und Liefervereinbarung mit BioNTech SE Gr\u00fcnwald, 10. September 2020 &#8211; Die Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) und die BioNTech SE, Mainz, Deutschland sind \u00fcbereingekommen, dass ihre Produktionstochtergesellschaften bei der Herstellung des COVID-19 Impfstoffes kooperieren werden. Die Produktionskapazit\u00e4ten bei Dermapharm stehen bereits zu Beginn der Impfstoffproduktion [&hellip;]<\/p>\n","protected":false},"author":24813,"featured_media":54373,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[261,447],"tags":[496],"class_list":["post-33909","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-ad-hoc-mitteilungen","category-news","tag-496"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>10. September 2020 | Dermapharm Holding SE schlie\u00dft Kooperations- und Liefervereinbarung mit BioNTech SE - cometis AG<\/title>\n<meta name=\"description\" content=\"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"10. September 2020 | Dermapharm Holding SE schlie\u00dft Kooperations- und Liefervereinbarung mit BioNTech SE - cometis AG\" \/>\n<meta property=\"og:description\" content=\"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-10T13:50:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-12T13:16:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6\"},\"headline\":\"10. September 2020 | Dermapharm Holding SE schlie\u00dft Kooperations- und Liefervereinbarung mit BioNTech SE\",\"datePublished\":\"2020-09-10T13:50:30+00:00\",\"dateModified\":\"2022-05-12T13:16:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/\"},\"wordCount\":494,\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"keywords\":[\"2020\"],\"articleSection\":[\"Dermapharm Ad-Hoc-Mitteilungen\",\"News\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/\",\"url\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/\",\"name\":\"10. September 2020 | Dermapharm Holding SE schlie\u00dft Kooperations- und Liefervereinbarung mit BioNTech SE - cometis AG\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"datePublished\":\"2020-09-10T13:50:30+00:00\",\"dateModified\":\"2022-05-12T13:16:51+00:00\",\"description\":\"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"caption\":\"Icon Newsroom_news\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dev.cometis.de\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\/\/dev.cometis.de\/de\/author\/assistenz-cometis-ag\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"10. September 2020 | Dermapharm Holding SE schlie\u00dft Kooperations- und Liefervereinbarung mit BioNTech SE - cometis AG","description":"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"de_DE","og_type":"article","og_title":"10. September 2020 | Dermapharm Holding SE schlie\u00dft Kooperations- und Liefervereinbarung mit BioNTech SE - cometis AG","og_description":"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.","og_url":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/","og_site_name":"cometis AG","article_published_time":"2020-09-10T13:50:30+00:00","article_modified_time":"2022-05-12T13:16:51+00:00","og_image":[{"url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","width":1,"height":1,"type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"Assistenz cometis AG","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#article","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6"},"headline":"10. September 2020 | Dermapharm Holding SE schlie\u00dft Kooperations- und Liefervereinbarung mit BioNTech SE","datePublished":"2020-09-10T13:50:30+00:00","dateModified":"2022-05-12T13:16:51+00:00","mainEntityOfPage":{"@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/"},"wordCount":494,"publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","keywords":["2020"],"articleSection":["Dermapharm Ad-Hoc-Mitteilungen","News"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/","url":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/","name":"10. September 2020 | Dermapharm Holding SE schlie\u00dft Kooperations- und Liefervereinbarung mit BioNTech SE - cometis AG","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","datePublished":"2020-09-10T13:50:30+00:00","dateModified":"2022-05-12T13:16:51+00:00","description":"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","caption":"Icon Newsroom_news"},{"@type":"WebSite","@id":"https:\/\/dev.cometis.de\/de\/#website","url":"https:\/\/dev.cometis.de\/de\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.cometis.de\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/dev.cometis.de\/de\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/dev.cometis.de\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/dev.cometis.de\/de\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/posts\/33909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/users\/24813"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/comments?post=33909"}],"version-history":[{"count":2,"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/posts\/33909\/revisions"}],"predecessor-version":[{"id":84090,"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/posts\/33909\/revisions\/84090"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/media\/54373"}],"wp:attachment":[{"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/media?parent=33909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/categories?post=33909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dev.cometis.de\/de\/wp-json\/wp\/v2\/tags?post=33909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}